FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387130679> ?p ?o ?g. }

• W4387130679 abstract "Abstract Background The ORBE II study aimed to describe the characteristics and clinical outcomes of adult patients with severe eosinophilic asthma (SEA) treated with benralizumab in a real-world setting in Spain. Methods ORBE II (NCT04648839) was an observational, retrospective cohort study in adult SEA patients who had been prescribed benralizumab. Demographic and clinical data of 204 SEA patients were collected 12 months prior to benralizumab initiation (baseline) and at follow-up. Exacerbation rate, asthma symptoms, maintenance oral corticosteroid (OCS) use and lung function were evaluated, among other variables. Results A total of 204 SEA patients were evaluated. Mean (standard deviation, SD) age of the study population was 56.4 (12.4) years, 62.3% were women and mean (SD) duration of asthma was 15.1 (12.7) years. Median (Q1–Q3) follow-up duration was 19.5 (14.2–24.2) months. At baseline, 72.6% of the overall population (OP) presented blood eosinophil counts ≥ 300 cells/µL; 36.8% had comorbid chronic rhinosinusitis with nasal polyps (CRSwNP); 84.8% reported at least one severe exacerbation, and 29.1% were OCS-dependent. At 1 year of follow-up, patients receiving benralizumab treatment had a 85.6% mean reduction in exacerbations from baseline, and 81.4% of patients achieved zero exacerbations. We also found a clinically relevant mean (SD) increase in pre-bronchodilator (BD) FEV 1 of 331 (413) mL, with 66.7% of patients achieving a pre-BD FEV 1 increase ≥ 100 mL, and 46.3% of patients achieving a pre-BD FEV 1 ≥ 80% of predicted. Regarding symptom control, 73.8% of the OP obtained an ACT score ≥ 20 points. After 1 year of follow-up, mean reduction in the daily OCS dose was 70.5%, and complete OCS withdrawal was achieved by 52.8% of the OCS-dependent patients. Almost half (43.7%) of the OP on benralizumab met all four criteria for clinical remission. Patients with concomitant CRSwNP obtained similar or enhanced outcomes. Conclusions These data support the real-world benefits of benralizumab in SEA patients, and particularly in those with concomitant CRSwNP. Trial registration NCT04648839." @default.
• W4387130679 created "2023-09-29" @default.
• W4387130679 creator A5001626495 @default.
• W4387130679 creator A5002774613 @default.
• W4387130679 creator A5013680071 @default.
• W4387130679 creator A5018421636 @default.
• W4387130679 creator A5021025712 @default.
• W4387130679 creator A5022789424 @default.
• W4387130679 creator A5026694285 @default.
• W4387130679 creator A5028442597 @default.
• W4387130679 creator A5031843224 @default.
• W4387130679 creator A5032982319 @default.
• W4387130679 creator A5050197179 @default.
• W4387130679 creator A5053326328 @default.
• W4387130679 creator A5056957769 @default.
• W4387130679 creator A5057222143 @default.
• W4387130679 creator A5065441304 @default.
• W4387130679 creator A5068515829 @default.
• W4387130679 creator A5068710948 @default.
• W4387130679 creator A5069565773 @default.
• W4387130679 creator A5074126079 @default.
• W4387130679 creator A5075122115 @default.
• W4387130679 creator A5092959795 @default.
• W4387130679 creator A5012776774 @default.
• W4387130679 date "2023-09-28" @default.
• W4387130679 modified "2023-10-16" @default.
• W4387130679 title "Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study" @default.
• W4387130679 cites W2014317758 @default.
• W4387130679 cites W2086332783 @default.
• W4387130679 cites W2098276532 @default.
• W4387130679 cites W2119706375 @default.
• W4387130679 cites W2120018683 @default.
• W4387130679 cites W2150035260 @default.
• W4387130679 cites W2402745597 @default.
• W4387130679 cites W2511120040 @default.
• W4387130679 cites W2513258422 @default.
• W4387130679 cites W2520152440 @default.
• W4387130679 cites W2578016795 @default.
• W4387130679 cites W2610113239 @default.
• W4387130679 cites W2616424562 @default.
• W4387130679 cites W2619633721 @default.
• W4387130679 cites W2755334065 @default.
• W4387130679 cites W2756181502 @default.
• W4387130679 cites W2888063502 @default.
• W4387130679 cites W2889065108 @default.
• W4387130679 cites W2899608945 @default.
• W4387130679 cites W2946192306 @default.
• W4387130679 cites W2955025518 @default.
• W4387130679 cites W2963852476 @default.
• W4387130679 cites W2971197956 @default.
• W4387130679 cites W2974441349 @default.
• W4387130679 cites W2977205771 @default.
• W4387130679 cites W2991954549 @default.
• W4387130679 cites W2994812624 @default.
• W4387130679 cites W2995165391 @default.
• W4387130679 cites W3008529720 @default.
• W4387130679 cites W3014800880 @default.
• W4387130679 cites W3034315108 @default.
• W4387130679 cites W3037599763 @default.
• W4387130679 cites W3038486779 @default.
• W4387130679 cites W3081076625 @default.
• W4387130679 cites W3082062213 @default.
• W4387130679 cites W3093042321 @default.
• W4387130679 cites W3093213532 @default.
• W4387130679 cites W3097151762 @default.
• W4387130679 cites W3104883674 @default.
• W4387130679 cites W3114098409 @default.
• W4387130679 cites W3130012184 @default.
• W4387130679 cites W3152894658 @default.
• W4387130679 cites W3165729005 @default.
• W4387130679 cites W3177427442 @default.
• W4387130679 cites W3184525349 @default.
• W4387130679 cites W3194122667 @default.
• W4387130679 cites W3198543579 @default.
• W4387130679 cites W3204022974 @default.
• W4387130679 cites W3213573559 @default.
• W4387130679 cites W4211171767 @default.
• W4387130679 cites W4212787287 @default.
• W4387130679 cites W4212936424 @default.
• W4387130679 cites W4213034991 @default.
• W4387130679 cites W4280586626 @default.
• W4387130679 cites W4281560606 @default.
• W4387130679 cites W4283776764 @default.
• W4387130679 cites W4294169818 @default.
• W4387130679 cites W4294740834 @default.
• W4387130679 cites W4308131998 @default.
• W4387130679 cites W4311156503 @default.
• W4387130679 cites W4313546568 @default.
• W4387130679 cites W4319083276 @default.
• W4387130679 cites W4322743728 @default.
• W4387130679 cites W4379058081 @default.
• W4387130679 cites W4382725975 @default.
• W4387130679 doi "https://doi.org/10.1186/s12931-023-02539-7" @default.
• W4387130679 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37770889" @default.
• W4387130679 hasPublicationYear "2023" @default.
• W4387130679 type Work @default.
• W4387130679 citedByCount "0" @default.
• W4387130679 crossrefType "journal-article" @default.
• W4387130679 hasAuthorship W4387130679A5001626495 @default.
• W4387130679 hasAuthorship W4387130679A5002774613 @default.

• next